OOIR: Observatory of International Research

Papers

(The H4-Index of Biochimica et Biophysica Acta-Reviews on Cancer is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Tumour cell-induced platelet aggregation in breast cancer: Scope of metal nanoparticles	371
Microbial influence on triggering and treatment of host cancer: An intestinal barrier perspective	253
Modeling bladder cancer in the laboratory: Insights from patient-derived organoids	187
Nutrition and dietary restrictions in cancer prevention	183
miRNAs and androgen deprivation therapy for prostate cancer	154
TSPAN1, a novel tetraspanin member highly involved in carcinogenesis and chemoresistance	153
The interaction of SET and protein phosphatase 2A as target for cancer therapy	126
Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique?	104
Advances in epigenetic modifications and cervical cancer research	104
Reflections on drug resistance to KRAS inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment	99
ESR1 activating mutations: From structure to clinical application	98
Uveal melanoma modeling in mice and zebrafish	93
Progress and challenges of immunotherapy in triple-negative breast cancer	87
Decoding the role of FOXP3 in esophageal cancer: Underlying mechanisms and therapeutic implications	79
Contribution of CXCR3-mediated signaling in the metastatic cascade of solid malignancies	78
Transcription factors in glioblastoma – Molecular pathogenesis and clinical implications	74
Extracellular vesicles in cancer therapy: Roles, potential application, and challenges	72
In what area of biology has a “new” type of cell death been discovered?	69
Epigenetic changes associated with Bacillus Calmette-Guerin (BCG) treatment in bladder cancer	69
Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature	63
Biomarkers in high grade serous ovarian cancer	63
Advances and prospects of mRNA vaccines in cancer immunotherapy	61
Dual perspective on autophagy in glioma: Detangling the dichotomous mechanisms of signaling pathways for therapeutic insights	61
S100A8 and S100A9 in Cancer	58
Insights into the role of connexins and specialized intercellular communication pathways in breast cancer: Mechanisms and applications	56

Long non-coding RNAs: Fundamental regulators and emerging targets of cancer stem cells	53
Fascin-1 in primary liver cancers, perspectives for targeted therapy	52
Targeting lipid metabolism in cancer metastasis	49
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting	47
Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors	46
Recent insights into RNA m5C methylation modification in hepatocellular carcinoma	46
Prognostic features of the tumour microenvironment in oesophageal adenocarcinoma	46
Targeting Cdc20 for cancer therapy	45
Long non-coding RNAs: A view to kill ovarian cancer	45
Small non-coding RNAs and pancreatic ductal adenocarcinoma: Linking diagnosis, pathogenesis, drug resistance, and therapeutic potential	45
Multiple impacts of Naa10p on cancer progression: Molecular functions and clinical prospects	45
Multifaceted roles of neutrophils in tumor microenvironment	45
Multiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy	45
The interplay of obesity, microbiome dynamics, and innovative anti-obesity strategies in the context of endometrial cancer progression and therapeutic approaches	45
Interleukin-21 as an adjuvant in cancer immunotherapy: Current advances and future directions	43
Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis	42
Editorial Board	42
Nondiploid cancer cells: Stress, tolerance and therapeutic inspirations	42
Epithelial-Mesenchymal Transition in Cancer: A Focus on Itraconazole, a Hedgehog Inhibitor	42